§ Legal
The content on the Vivre Labs website - including compound information, protocol descriptions, monitoring references, evidence summaries, FAQs, and educational explainers - is for educational and informational purposes only. It is not medical advice, a diagnosis, a prescription, a dosing instruction, or a recommendation that any specific compound, protocol, dose, or treatment is appropriate for you. If you have a medical condition, are pregnant or nursing, are taking medications, or have any other reason to seek personalised medical advice, consult a licensed healthcare provider in your jurisdiction.
The Platform describes compounds in distinct categories, described honestly: approved-class therapies (regulatory approval for specific indications); investigational compounds (in active clinical trials, e.g. Retatrutide) - identified as such, not presented as approved therapies; compounds with limited or contested human evidence (e.g. BPC-157, TB-500, Epithalon, DSIP) - limitations stated; and compounds with documented safety concerns - concerns stated explicitly. Dosing, frequency, duration, and reconstitution are not provided on the Platform and are never provided to you outside a clinical consultation.
Where any compound is used outside its approved regulatory indication, or where a compound is investigational and not yet approved, that use is within the physician-patient relationship, documented as off-label or investigational, conducted with explicit informed consent, and subject to the physician's clinical judgement. The Platform does not promote off-label or investigational use to the public.
Any prescription, dispensing, or supervised administration of any compound arises only within a relationship between you and a licensed treating physician practising in your market, supported by a registered clinical facility and a registered pharmacy. Vivre Labs does not, and the Platform does not, prescribe, dispense, or directly authorize any treatment. No AI tool, automated assessment, or content on the Platform constitutes a clinical decision.
The Platform is not for emergencies. If you are experiencing chest pain, difficulty breathing, severe injury, suicidal thoughts, severe allergic reaction, or any other emergency medical situation, call your local emergency services immediately. Do not use the Platform, our chat channels, or our enquiry form to seek emergency help.
Where the Platform discusses biomarker changes, body-composition outcomes, or other measurable results - including in any future cohort data we publish - those results reflect the populations and conditions in which the data was generated. Individual responses vary. No result described on the Platform should be interpreted as a promise, guarantee, or reasonable expectation of what will happen to any specific patient. Outcome data published by Vivre, when it exists, will be presented with sample size, time period, and variance.
Malaysia - Content on the Platform is not promotional material for any prescription medicine within the meaning of the Medicines (Advertisement and Sale) Act 1956 and the rules of the Medicine Advertisements Board (MAB). Indonesia - Content is not promotional material for any prescription medicine within the meaning of BPOM regulations. Thailand - Content is not promotional material for any prescription medicine within the meaning of the Drug Act B.E. 2510 and subsequent amendments. The final, counsel-certified market-specific disclaimers will replace this section at clinical launch.
While Vivre Labs is in a pre-launch / demo state, no actual clinical care is being delivered. Content on the Platform describes the operating model that will apply at clinical launch. Sample audits, illustrative biomarker values, and sample monitoring schedules are illustrative, not records of completed clinical care. Nothing in the demo content constitutes medical advice to any visitor.
For clinical questions: book a consultation through the Platform. For questions about this disclaimer: legal@vivre.[domain].
Are you 18 years of age or older?